Print

Adamis Pharmaceuticals Vaccine Technology Granted a Patent in Europe  
7/13/2011 8:39:01 AM

SAN DIEGO--(BUSINESS WIRE)--Adamis Pharmaceuticals Corporation (OTCBB:ADMP), today announced the technology which constitutes the basis of a novel cell-based cancer vaccine, TeloB-VAX, was recently granted a patent in Europe. A patent entitled “Somatic transgene immunization and related methods” has been issued. Although genetic vaccines (DNA) have been used, there remains a need to develop more effective methods to exploit their ability to induce a reproducible immune response. The present invention satisfies this need and provides related advantages as well. The issued claims offer broad protection of a technology platform developed by Dr. Maurizio Zanetti, Professor of Medicine and Director of the Laboratory of Immunology at the UC San Diego Moores Cancer Center.
//-->